AXER-204 is under clinical development by ReNetX Bio and currently in Phase II for Chronic Spinal Cord Injury. According to GlobalData, Phase II drugs for Chronic Spinal Cord Injury does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the AXER-204 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AXER-204 overview

AXER-204 is under development for the treatment of spinal cord injury, glaucoma, multiple sclerosis, optic neuritis, disorders with optic nerve injury, CNS axonal injuries and degenerative diseases. It consists of ectodomain of NgR1 fused to IgG1 and binds to Nogo-A, myelin-associated glycoprotein (MAG) and oligodendrocyte myelin glycoprotein (Omgp) ligands. It was also under development for the treatment of stroke.

ReNetX Bio overview

ReNetX Bio provide first-in-class therapeutics to treat injury/damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI), stroke, and glaucoma.

For a complete picture of AXER-204’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.